Journal Mobile Options
Table of Contents
Vol. 35, No. 5, 2012
Issue release date: May 2012
Section title: Original Report: Patient-Oriented, Translational Research
Am J Nephrol 2012;35:424–433
(DOI:10.1159/000337916)

Mycophenolate as Induction Therapy in Lupus Nephritis with Renal Function Impairment

Rivera F.a · Fulladosa X.b · Poveda R.b · Frutos M.A.c · García-Frías P.c · Ara J.d · Illescas L.e · López-Rubio E.e · Mérida E.f · Carreño A.a · Ballarín J.g · Fernández-Juárez G.h · Baltar J.i · Ramos C.j · Pons S.j · Oliet A.k · Vigil A.k · Praga M.f · Segarra A.l · Spanish Group for the Study of Glomerular Disease (GLOSEN)
aHospital General de Ciudad Real, Ciudad Real, bHospital Universitari de Bellvitge, Bellvitge, cHospital Universitario Carlos Haya, Malaga, dHospital Universitari Germans Trias i Pujol, Badalona, eHospital General Universitario de Albacete, Albacete, fHospital Universitario 12 de Octubre, Madrid, gFundació Puigvert, Barcelona, hFundación Hospital Alcorcón, Alcorcón, iHospital Universitario Central de Asturias, Oviedo, jHospital Clinic Universitari de Valencia, Valencia, kHospital Severo Ochoa, Madrid, y lHospital Vall d’Hebron, Vall d’Hebron, España

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
  • Reduced rates with a PPV account
read more

Direct: USD 38.00
Account: USD 26.50

Select

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select


Article / Publication Details

First-Page Preview
Abstract of Original Report: Patient-Oriented, Translational Research

Received: 1/23/2012
Accepted: 3/8/2012
Published online: 4/20/2012
Issue release date: May 2012

Number of Print Pages: 10
Number of Figures: 2
Number of Tables: 7

ISSN: 0250-8095 (Print)
eISSN: 1421-9670 (Online)

For additional information: http://www.karger.com/AJN

Abstract

Background: Mycophenolate (MF) is effective as induction therapy for lupus nephritis (LN) in patients with normal renal function; however, little is known about its role in patients with impaired renal failure. The purpose of this study was to evaluate the response to MF in LN and its association with baseline renal function. Methods: Data were obtained for 90 patients from 12 Spanish renal units who were receiving MF as induction therapy for LN. Patients were classified into 2 groups: group 1 (estimated glomerular filtration rate [eGFR] ≥60 ml/min/1.73 m2) and group 2 (eGFR <60 ml/min/ 1.73 m2). The primary outcome measure was the percentage of patients who achieved any response and its relationship with initial eGFR. The secondary outcome measures were the percentage of patients who achieved a complete response (CR) or partial response (PR) and the appearance of relapses during treatment and side effects. Results: At initiation of MF treatment, there were no differences in the main parameters between group 1 (n = 63; eGFR 87 ± 23 ml/min/ 1.73 m2) and group 2 (n = 27; eGFR 44 ± 12 ml/min/1.73 m2). Exposure to prednisone and MF was similar. The percentages of patients who achieved a response in groups 1 and 2 were, respectively, 69.2 and 43.8% at 6 months and 81.3 and 73.7% at 12 months. CR was more frequent in group 1, whereas PR was similar in both groups. Four patients relapsed and side effects were unremarkable. Conclusions: MF is effective and safe as induction therapy for LN, and response is even achieved in patients with baseline renal impairment.

© 2012 S. Karger AG, Basel


  

Author Contacts

Dr. Francisco Rivera
Sección de Nefrología
Hospital General de Ciudad Real
ES–13004 Ciudad Real (Spain)
Tel. +34 92 627 8000, E-Mail friverahdez@senefro.org

/p>

  

Article Information

Received: January 23, 2012
Accepted: March 8, 2012
Published online: April 20, 2012
Number of Print Pages : 10
Number of Figures : 2, Number of Tables : 7, Number of References : 36

  

Publication Details

American Journal of Nephrology

Vol. 35, No. 5, Year 2012 (Cover Date: May 2012)

Journal Editor: Bakris G. (Chicago, Ill.)
ISSN: 0250-8095 (Print), eISSN: 1421-9670 (Online)

For additional information: http://www.karger.com/AJN


Article / Publication Details

First-Page Preview
Abstract of Original Report: Patient-Oriented, Translational Research

Received: 1/23/2012
Accepted: 3/8/2012
Published online: 4/20/2012
Issue release date: May 2012

Number of Print Pages: 10
Number of Figures: 2
Number of Tables: 7

ISSN: 0250-8095 (Print)
eISSN: 1421-9670 (Online)

For additional information: http://www.karger.com/AJN


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.